UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000028561
Receipt No. R000032567
Scientific Title A phase II study of Nivolumab re-challenge therapy in patients with advanced non-small cell lung cancer who responded to prior PD-1/L1 inhibitors (WJOG9616L)
Date of disclosure of the study information 2017/08/08
Last modified on 2019/08/09 09:37:22

No. Disposal Last modified on Item of update
1 Insert 2017/08/07 12:46:16
2 Update 2017/09/05 09:00:21 Organization
Organization
Organization
Category of Funding Organization
Nationality of Funding Organization
Nationality of Funding Organization
3 Update 2017/10/13 15:35:12 Organization
Organization
Organization
Category of Funding Organization
4 Update 2017/10/17 17:45:45 Recruitment status
Anticipated trial start date
5 Update 2018/02/13 10:17:19 Key inclusion criteria
6 Update 2019/01/25 09:54:12 Primary outcomes
Primary outcomes
Key secondary outcomes
Key secondary outcomes
7 Update 2019/01/25 09:57:25 Interventions/Control_1
Interventions/Control_1
Key inclusion criteria
Key exclusion criteria
8 Update 2019/01/25 10:06:47 Last name of lead principal investigator
Last name of lead principal investigator
Organization
Email
Organization1
Tel1
Secondary IDs
Study ID_1
Org. issuing International ID_1
Org. issuing International ID_1
9 Update 2019/08/09 09:33:31 Date of IRB
Last follow-up date
10 Update 2019/08/09 09:37:22 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Address
Organization
Organization
Address
Address
Tel
Email


Contact us.